Clinical Trial Update: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a quadruplet combination of daratumumab, carfilzomib, lenalidomide, and low-dose dexamethasone (DKRd) in newly diagnosed multiple mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Chicago | Conditions: Myeloma, Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING